Bausch Health (BHC)
(Delayed Data from NYSE)
$7.19 USD
-0.10 (-1.37%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $7.20 +0.01 (0.14%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BHC 7.19 -0.10(-1.37%)
Will BHC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BHC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BHC
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
Bausch Health (BHC) Q1 Earnings and Revenues Miss Estimates
BHC: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Bausch (BHC) Rating Upgrade to Buy
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
Other News for BHC
Carl Icahn's Firm Expands Grip on Icahn Enterprises LP Holding
Carl Icahn's Strategic Acquisition in Icahn Enterprises LP
Bausch Health call volume above normal and directionally bullish
Bausch files patent suit against Norwich over generic Xifaxan
Bausch Health Defends XIFAXAN® Patent Again